title: Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
abstract: The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies.
authors.affiliation: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK. lucy.dorrell@imm.ox.ac.uk
authors.forename: Lucy
authors.initials: L
authors.lastname: Dorrell
authors.forename: Patricia
authors.initials: P
authors.lastname: Williams
authors.forename: Annie
authors.initials: A
authors.lastname: Suttill
authors.forename: Denise
authors.initials: D
authors.lastname: Brown
authors.forename: Joanna
authors.initials: J
authors.lastname: Roberts
authors.forename: Christopher
authors.initials: C
authors.lastname: Conlon
authors.forename: Tomás
authors.initials: T
authors.lastname: Hanke
authors.forename: Andrew
authors.initials: A
authors.lastname: McMichael
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018984:Epitopes, T-Lymphocyte; D005260:Female; D015683:Gene Products, gag / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D016655:HIV Core Protein p24 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019444:Vaccines, DNA; D019562:Viral Load; D014764:Viral Proteins / Q000276:immunology; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; D018984:Epitopes, T-Lymphocyte; D015683:Gene Products, gag; D015488:HIV Antigens; D016655:HIV Core Protein p24; C505104:MVA-HIVA vaccine; D019444:Vaccines, DNA; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1